7503. Piroheptine
Nomenclature
CAS number: 16378-21-5
3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl-2-methylpyrrolidine. C22H25N; mol wt 303.44.
C 87.08%, H 8.30%, N 4.62%.
Description and references
Prepn: NL 6609280; Y. Deguchi et al., US 3454595 (1967, 1969 both to Fujisawa). Crystal structure: Y. Tokuma et al., Bull. Chem. Soc. Jpn. 44, 2665 (1971). Pharmacological studies: M. Hitomi et al., Arzneim.-Forsch. 22, 953, 961 (1972). In vitro study: T. Ohashi et al., ibid. 966. Metabolism: Y. Tokuma et al., Bull. Chem. Soc. Jpn. 48, 294 (1975). Clinical pharmacology: A. Barbeau, Annu. Rev. Pharmacol. 14, 91 (1974). Toxicity study: M. Hitomi et al., Arzneim.-Forsch. 22, 961 (1972).
Properties
Liquid, bp4 167°. uv max (95% ethanol): 240 nm (ε 12100).Derivative
Hydrochloride.Nomenclature
CAS number: 16378-22-6
Trimol (Fujisawa). C22H25N.HCl; mol wt 339.90.
C 77.74%, H 7.71%, N 4.12%, Cl 10.43%.
Properties
Crystals, mp 250-253°. LD50 in male mice, rats (mg/kg): 153, 600 orally; 19, 17 i.v.; 95, 110 i.p.; 109, 330 s.c. (Hitomi).Therapeutic Category
Antiparkinsonian.
Keywords
Antiparkinsonian